BCMA/CD47-directed UCAR-T cells demonstrated efficacy against MM and prolonged the survival of tumor-engrafted NCG mice in vivo, which provides a potential strategy for the development of a novel “off-the-shelf” cellular immunotherapies for the treatment of multiple myeloma. The gene discussed is CD47; the disease is plasma cell myeloma.